the world's third-largest generic drug maker changed its name to actavis, a company watson bought last fall. c.e.o. paul bisaro says its no stranger to growth through acquisitions. >> in the short-term we'll be looking for add-on acquisitions whether it's in the branded space where we continue to be very aggressive in the areas of women's health and urology trying to find new therapies we can bring to market. i think a bigger transaction for us would probably await 2014, or 2015. >> reporter: with acquisitions come redundancies, actavis is cutting jobs and moving operations out of its original corona, california facility. >> most of the products that are manufactured in that facility will be moving to our florida facility or our elizabeth, n.j. facility, so there will be some additional increases in people in those facilities. we'll also be moving to some overseas locations. >> reporter: investors have seen a nice run-up in the shares this year, though they've been hovering between $80 and $90 a share since last fall. >> since 2008 we've had a compound annual growth rate of over 30%. and every year sinc